188 related articles for article (PubMed ID: 36043494)
1. Upregulation of p53 through induction of MDM2 degradation: improved potency through the introduction of an alkylketone sidechain on the anthraquinone core.
Tripathi R; Anifowose A; Lu W; Yang X; Wang B
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):2370-2381. PubMed ID: 36043494
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of p53 through induction of MDM2 degradation: Anthraquinone analogs.
Draganov AB; Yang X; Anifowose A; De La Cruz LKC; Dai C; Ni N; Chen W; De Los Santos Z; Gu L; Zhou M; Wang B
Bioorg Med Chem; 2019 Sep; 27(17):3860-3865. PubMed ID: 31324563
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of p53 through induction of MDM2 degradation: Amino acid prodrugs of anthraquinone analogs.
Anifowose A; Yuan Z; Yang X; Pan Z; Zheng Y; Zhang Z; Wang B
Bioorg Med Chem Lett; 2020 Jan; 30(2):126786. PubMed ID: 31753697
[TBL] [Abstract][Full Text] [Related]
4. Inducing Apoptosis through Upregulation of p53: Structure-Activity Exploration of Anthraquinone Analogs.
Anifowose A; Agbowuro AA; Tripathi R; Lu W; Tan C; Yang X; Wang B
Med Chem Res; 2020 Jul; 29(7):1199-1210. PubMed ID: 32719577
[TBL] [Abstract][Full Text] [Related]
5. Enhanced cytotoxicity of prenylated chalcone against tumour cells via disruption of the p53-MDM2 interaction.
Leão M; Soares J; Gomes S; Raimundo L; Ramos H; Bessa C; Queiroz G; Domingos S; Pinto M; Inga A; Cidade H; Saraiva L
Life Sci; 2015 Dec; 142():60-5. PubMed ID: 26475964
[TBL] [Abstract][Full Text] [Related]
6. Degradation of MDM2 by the interaction between berberine and DAXX leads to potent apoptosis in MDM2-overexpressing cancer cells.
Zhang X; Gu L; Li J; Shah N; He J; Yang L; Hu Q; Zhou M
Cancer Res; 2010 Dec; 70(23):9895-904. PubMed ID: 20935220
[TBL] [Abstract][Full Text] [Related]
7. The anaphase-promoting complex/cyclosome is an E3 ubiquitin ligase for Mdm2.
He Y; Tollini L; Kim TH; Itahana Y; Zhang Y
Cell Cycle; 2014; 13(13):2101-9. PubMed ID: 24804778
[TBL] [Abstract][Full Text] [Related]
8. The RASSF6 tumor suppressor protein regulates apoptosis and the cell cycle via MDM2 protein and p53 protein.
Iwasa H; Kudo T; Maimaiti S; Ikeda M; Maruyama J; Nakagawa K; Hata Y
J Biol Chem; 2013 Oct; 288(42):30320-30329. PubMed ID: 24003224
[TBL] [Abstract][Full Text] [Related]
9. Escape, or Vanish: Control the Fate of p53 through MDM2-Mediated Ubiquitination.
Wei J; Yang Y; Lu M; Xu L; Liu F; Yuan Z; Bao Q; Jiang Z; Xu X; Guo X; Zhang X; You Q; Sun H
Anticancer Agents Med Chem; 2015; 16(2):174-89. PubMed ID: 26343143
[TBL] [Abstract][Full Text] [Related]
10. Structural and functional comparison of the RING domains of two p53 E3 ligases, Mdm2 and Pirh2.
Shloush J; Vlassov JE; Engson I; Duan S; Saridakis V; Dhe-Paganon S; Raught B; Sheng Y; Arrowsmith CH
J Biol Chem; 2011 Feb; 286(6):4796-808. PubMed ID: 21084285
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of MDM2 by a Rhein-Derived Compound AQ-101 Suppresses Cancer Development in SCID Mice.
Gu L; Zhang H; Liu T; Draganov A; Yi S; Wang B; Zhou M
Mol Cancer Ther; 2018 Feb; 17(2):497-507. PubMed ID: 29282301
[TBL] [Abstract][Full Text] [Related]
12. Crosstalk between MYCN and MDM2-p53 signal pathways regulates tumor cell growth and apoptosis in neuroblastoma.
He J; Gu L; Zhang H; Zhou M
Cell Cycle; 2011 Sep; 10(17):2994-3002. PubMed ID: 21862876
[TBL] [Abstract][Full Text] [Related]
13. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor.
Manfredi JJ
Genes Dev; 2010 Aug; 24(15):1580-9. PubMed ID: 20679392
[TBL] [Abstract][Full Text] [Related]
14. P53 mRNA controls p53 activity by managing Mdm2 functions.
Candeias MM; Malbert-Colas L; Powell DJ; Daskalogianni C; Maslon MM; Naski N; Bourougaa K; Calvo F; Fåhraeus R
Nat Cell Biol; 2008 Sep; 10(9):1098-105. PubMed ID: 19160491
[TBL] [Abstract][Full Text] [Related]
15. UBE4B, a ubiquitin chain assembly factor, is required for MDM2-mediated p53 polyubiquitination and degradation.
Wu H; Leng RP
Cell Cycle; 2011 Jun; 10(12):1912-5. PubMed ID: 21558803
[TBL] [Abstract][Full Text] [Related]
16. Mouse models of Mdm2 and Mdm4 and their clinical implications.
Xiong S
Chin J Cancer; 2013 Jul; 32(7):371-5. PubMed ID: 23327795
[TBL] [Abstract][Full Text] [Related]
17. Acetylation-dependent regulation of MDM2 E3 ligase activity dictates its oncogenic function.
Nihira NT; Ogura K; Shimizu K; North BJ; Zhang J; Gao D; Inuzuka H; Wei W
Sci Signal; 2017 Feb; 10(466):. PubMed ID: 28196907
[TBL] [Abstract][Full Text] [Related]
18. Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells.
Ciardullo C; Aptullahoglu E; Woodhouse L; Lin WY; Wallis JP; Marr H; Marshall S; Bown N; Willmore E; Lunec J
Haematologica; 2019 Dec; 104(12):2429-2442. PubMed ID: 31004033
[TBL] [Abstract][Full Text] [Related]
19. FKBP25, a novel regulator of the p53 pathway, induces the degradation of MDM2 and activation of p53.
Ochocka AM; Kampanis P; Nicol S; Allende-Vega N; Cox M; Marcar L; Milne D; Fuller-Pace F; Meek D
FEBS Lett; 2009 Feb; 583(4):621-6. PubMed ID: 19166840
[TBL] [Abstract][Full Text] [Related]
20. 2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol inhibits MDM2 and induces apoptosis in breast cancer cells through a p53-independent pathway.
Xu J; Han M; Shen J; Guan Q; Bai Z; Lang B; Zhang H; Li Z; Zuo D; Zhang W; Wu Y
Cancer Lett; 2016 Dec; 383(1):9-17. PubMed ID: 27693458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
